Handa Pharmaceuticals, Inc.

TPEX:6620 Stock Report

Market Cap: NT$8.6b

Handa Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Handa Pharmaceuticals has a total shareholder equity of NT$2.9B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$3.1B and NT$244.7M respectively. Handa Pharmaceuticals's EBIT is NT$525.4M making its interest coverage ratio -11.5. It has cash and short-term investments of NT$2.5B.

Key information

0%

Debt to equity ratio

NT$0

Debt

Interest coverage ratio-11.5x
CashNT$2.53b
EquityNT$2.90b
Total liabilitiesNT$244.70m
Total assetsNT$3.15b

Recent financial health updates

We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business Growth

Dec 29
We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business Growth

Recent updates

Handa Pharmaceuticals'(GTSM:6620) Share Price Is Down 26% Over The Past Three Years.

Feb 24
Handa Pharmaceuticals'(GTSM:6620) Share Price Is Down 26% Over The Past Three Years.

We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business Growth

Dec 29
We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business Growth

Financial Position Analysis

Short Term Liabilities: 6620's short term assets (NT$2.8B) exceed its short term liabilities (NT$156.0M).

Long Term Liabilities: 6620's short term assets (NT$2.8B) exceed its long term liabilities (NT$88.7M).

Debt to Equity History and Analysis

Debt Level: 6620 is debt free.

Reducing Debt: 6620 had no debt 5 years ago.

Debt Coverage: 6620 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 6620 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y